Evolving Global CGM Market

Diabetes affects over 500 million people worldwide, creating significant healthcare and economic challenges, with many cases going undiagnosed. The growing prevalence of Type 1, Type 2, and prediabetes is driving rapid adoption of Continuous Glucose Monitoring (CGM) systems. The global CGM market is led by Abbott, Dexcom, accounting for over 90% of the market share. Abbott’s competitively priced devices have a broad global reach, while Dexcom holds a strong position in the U.S. The U.S. and EU are key markets, driven by higher income levels, technological readiness, and reimbursement support. In contrast, limited reimbursement in China and Japan hampers wider use. Distribution strategies vary by region, with retail channels dominant in the U.S. and China, and reimbursement-based models more common in Europe. Innovation and integration with digital health platforms—led by newer players such as Senseonics and Nemaura Medical—is shaping the future of accessible, connected diabetes care.